이동윤 교수

A few studies have investigated the effects of laparoscopic cystectomy for endometrioma on ovarian reserve using serum anti-Müllerian hormone (AMH) levels and have shown inconsistent results. This prospective study was performed to estimate early changes in serum AMH after laparoscopic surgery for endometrioma. In 27 women aged 21-46 years who underwent laparoscopic unilateral cystectomy (n = 13) or oophorectomy (n = 14) for endometrioma, we measured pre- and postoperative serum AMH levels at ba

<b>Background:</b> Several preclinical and clinical studies have suggested that <i>BRCA</i>-mutation carriers may have decreased ovarian reserve. However, data in this area are limited and inconsistent, especially in young breast cancer patients. <b>Objective:</b> This study evaluated the association between <i>BRCA</i> mutation status and serum anti-Müllerian hormone (AMH) level in young, reproductive-aged patients with breast cancer. <b>Materials and Methods:</b> Patients ≤ 40 years of age wit

The effects of menopausal hormone therapy (MHT) on non-alcoholic fatty liver disease (NAFLD) were compared based on the route of estrogen administration. The study included 368 postmenopausal women who received MHT for 12 months. Patients were divided into transdermal (n = 75) and oral (n = 293) groups based on the estrogen route. Changes in the prevalence of NAFLD were compared between the two groups before and after 12 months of MHT. In addition, differences in the progression of NAFLD after M

Cognitive impairment is significantly associated with lower BMD in postmenopausal women. This finding suggests that cognitive aging is clearly multifactorial, but estrogen deficiency may be one of the contributing factors.

Our results suggest that the sFRP4 c1019G>A polymorphism may be one of the genetic factors affecting lumbar spine BMD in postmenopausal Korean women.

This study was performed to evaluate serum estradiol level in postmenopausal women using oral menopausal hormone therapy (MHT) with different doses and formulations of estrogens. A total of 344 postmenopausal women who received oral MHT was included in this cross-sectional study. Serum estradiol level was compared according to formulation (estradiol hemihydrate [EH] or valerate [EV], conjugated estrogen [CE]) and dose (estradiol 1 or 2 mg, CE 0.45 or 0.625 mg) of the estrogens. Mean age and year

NAFLD is negatively associated with BMD in postmenopausal women. A longitudinal study is recommended.

In this study a potential magnetic resonance (MR) T_2 contrast agent was developed systematically based on heparin-coated superparamagnetic iron oxide (SPIO) nanoparticles. Dextran-coated SPIO, which is commercially available as Feridex^®, was prepared for the control group. The size of the crystalline core was adjusted to provide suitable relaxometric properties. Compared to the uncoated SPIO, the heparin or dextran coating provided a better dispersion of SPIO nanoparticles in solution. The zet

This preliminary study suggests that an add-back regimen containing estradiol valerate and norethisterone acetate may have better efficacy in terms of quality of life, hypoestrogenism-associated symptoms, and bone mineral density.